Antidepressant Drugs Market is Expected to Reach $20.6 billion by 2031 - Eli Lilly and Company, GlaxoSmithKline Plc, LGM Pharma LLC

The global Antidepressant Drugs Market was valued at US $14.3 billion in 2022 and is projected to reach US$20.6 billion by 2031, expanding at a CAGR of 5.56% from 2024 to 2031.

Antidepressant drugs function by elevating levels of neurotransmitters in the brain, such as serotonin and noradrenaline, which are associated with mood and emotion. These medications are commonly prescribed for conditions including major depressive disorder, anxiety disorders, premenstrual dysphoric disorder (PMDD), and bipolar depression.

Get a Free Sample Research PDF - https://www.datamintelligence.com/download-sample/antidepressant-drugs-market

Key Developments

In March 2023, Alembic Pharmaceuticals received approval from the U.S. Food & Drug Administration (FDA) to market Brexpiprazole tablets in various strengths (0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg). These tablets are indicated as an adjunctive therapy to antidepressants for treating major depressive disorder.
In November 2022, Luye Pharma Group obtained marketing approval from China's National Medical Products Administration (NMPA) for Ruoxinlin (toludesvenlafaxine hydrochloride), a triple monoamine reuptake inhibitor, designed to treat major depressive disorder.

Market Dynamics:

Increasing Research and Developments for Antidepressant DrugsMarket Segment Analysis

The global antidepressant drugs market has experienced substantial growth due to recent advancements in research and development. Depression is typically diagnosed through medical history, clinical assessments, and imaging findings. Continued innovation in treatments for major depressive disorder is driving this market expansion.

For example, in August 2023, Novartis AG announced that its drug Onfasprodil is in Phase II clinical development for treatment-resistant depression. Onfasprodil (MIJ-821) is aimed at addressing treatment-resistant depression and major depressive disorder (MDD).

Market Segment Analysis

By Drug Class: Monoamine oxidase inhibitors, Norepinephrine-Dopamine Reuptake Inhibitor, Serotonin-norepinephrine reuptake inhibitors, Selective serotonin reuptake inhibitors, Tricyclic antidepressants

By Depression Disorder: Major depressive disorder, Obsessive-compulsive disorder, Generalized anxiety disorder, Panic disorder and others

By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Get Customization in the report as per your requirements - https://www.datamintelligence.com/customize/antidepressant-drugs-market

Major Key players

• Eli Lilly and Company
• GlaxoSmithKline Plc.
• LGM Pharma LLC
• Apotex Inc.
• Zheijiang Huahai Pharmaceutical Co. Ltd.
• AstraZeneca Plc.
• Takeda Pharmaceutical Co. Ltd
• Pfizer Inc.
• Aurobindo Pharma Limited
• Merck KGaA

*Note:

Additionally, I wanted to highlight that the full version of the report includes an in-depth analysis of emerging players and startups, which will provide valuable insights into the evolving market landscape and key strategies being adopted.

Related Reports:

Antiulcerant Drugs Market: https://datamintelligence.com/research-report/antiulcerant-drugs-market

Antiviral Drugs Market: https://datamintelligence.com/research-report/antiviral-drugs-market

Affiliate Marketing Request here: https://www.datamintelligence.com/affiliate-marketing

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.